This document summarizes a conference on chronic diseases and patients' rights in the framework of EU healthcare sustainability. It discusses how healthcare systems can remain active over time despite problems and crises by balancing solidarity and individualistic values with available resources and increasing costs. It also examines how increasing population age and disease prevalence are contributing to rising healthcare needs and costs. An alternative approach is proposed that bases healthcare financing on quality of care rather than amount of services provided. The document advocates for more objective and transparent criteria in healthcare systems that focus on health outcomes rather than diseases.
Sustainability and transition - Maris Jesse, EstoniaOECD Governance
This presentation was made by Maris Jesse, Estonia, at the 2nd Health Systems Joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
Digital technologies and data have the potential to transform health and care across the European Union by:
1) Allowing citizens secure access to their health data and enabling health providers to exchange information across borders.
2) Pooling health data for research and personalized medicine to allow targeted and faster diagnosis and treatment.
3) Empowering citizens through digital tools to better monitor and manage their health while also facilitating interaction with doctors and care providers.
The European Commission views patient safety as a priority and has taken several steps to promote it. These include establishing a patient safety working group, funding projects like EUNetPaS, and adopting a recommendation that encourages member states to develop national patient safety policies, empower patients, establish reporting systems, promote a culture of safety, and conduct research. While progress has been made, more work is still needed at the member state level, and the EU aims to play a supportive role through knowledge sharing, best practices, and continued coordination across Europe.
The BRIDGE Health project involves 31 institutes from 16 European countries. It aims to develop a strategic policy paper and technical blueprints for a future integrated European health information system covering both public health and healthcare. The project will disseminate results through technical reports, workshops, and meetings to target audiences like policymakers, researchers, and the general public. It seeks to ensure sustainability of health information activities and enhance synergy between domains like population health monitoring, disease registries, and clinical data collection.
Workshop 7 - Brainstorming & Policy Development session: Prevention
"EUROCAT Study on Prevention of Congenital Anomalies"
Dr. Domenica Taruscio, ISS Italy
EunetHTA Planned and Ongoing Projects database (POP DB)Patrice Chalon
The contents of this poster arise from an EU-funded project and sole responsibility for its contents lies with the authors. The Planned and Ongoing Projects database is used by over 73% of partners to search for similar projects, with 12-20% of projects found to be similar and 7-10% having the same topic. It is delivered through project management, coding, and content provision from various European organizations.
This document summarizes a conference on chronic diseases and patients' rights in the framework of EU healthcare sustainability. It discusses how healthcare systems can remain active over time despite problems and crises by balancing solidarity and individualistic values with available resources and increasing costs. It also examines how increasing population age and disease prevalence are contributing to rising healthcare needs and costs. An alternative approach is proposed that bases healthcare financing on quality of care rather than amount of services provided. The document advocates for more objective and transparent criteria in healthcare systems that focus on health outcomes rather than diseases.
Sustainability and transition - Maris Jesse, EstoniaOECD Governance
This presentation was made by Maris Jesse, Estonia, at the 2nd Health Systems Joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
Digital technologies and data have the potential to transform health and care across the European Union by:
1) Allowing citizens secure access to their health data and enabling health providers to exchange information across borders.
2) Pooling health data for research and personalized medicine to allow targeted and faster diagnosis and treatment.
3) Empowering citizens through digital tools to better monitor and manage their health while also facilitating interaction with doctors and care providers.
The European Commission views patient safety as a priority and has taken several steps to promote it. These include establishing a patient safety working group, funding projects like EUNetPaS, and adopting a recommendation that encourages member states to develop national patient safety policies, empower patients, establish reporting systems, promote a culture of safety, and conduct research. While progress has been made, more work is still needed at the member state level, and the EU aims to play a supportive role through knowledge sharing, best practices, and continued coordination across Europe.
The BRIDGE Health project involves 31 institutes from 16 European countries. It aims to develop a strategic policy paper and technical blueprints for a future integrated European health information system covering both public health and healthcare. The project will disseminate results through technical reports, workshops, and meetings to target audiences like policymakers, researchers, and the general public. It seeks to ensure sustainability of health information activities and enhance synergy between domains like population health monitoring, disease registries, and clinical data collection.
Workshop 7 - Brainstorming & Policy Development session: Prevention
"EUROCAT Study on Prevention of Congenital Anomalies"
Dr. Domenica Taruscio, ISS Italy
EunetHTA Planned and Ongoing Projects database (POP DB)Patrice Chalon
The contents of this poster arise from an EU-funded project and sole responsibility for its contents lies with the authors. The Planned and Ongoing Projects database is used by over 73% of partners to search for similar projects, with 12-20% of projects found to be similar and 7-10% having the same topic. It is delivered through project management, coding, and content provision from various European organizations.
Mirjam Maeusezahl: Joint External Evaluations (JEE) – Country experiences: Sw...THL
The document discusses Switzerland's participation in the Joint External Evaluation (JEE) conducted by the World Health Organization. It provides details on Switzerland's implementation of the International Health Regulations, the timeline and milestones of the JEE process, and lessons learned. Key results showed room for improvement in antimicrobial resistance detection and response as well as strengthening surveillance systems for zoonotic diseases. Switzerland adapted the WHO National Action Plan template to monitor progress in addressing JEE recommendations internally.
Who workshop aids 2014 hivtb integrationZahed Islam
This document summarizes an AIDS 2014 workshop on increasing access to tuberculosis (TB) services for people who inject drugs in Ukraine through integrated care. It describes how non-governmental organizations (NGOs) in Ukraine provide TB screening, testing, and treatment to people who inject drugs through outreach programs and by establishing integrated care centers that provide medical and psychosocial support services for patients with drug abuse, HIV, and TB comorbidities in a single location. As of 2014, these efforts had established 88 opioid substitution therapy sites and detected 659 TB cases through screening over 10,000 people who inject drugs. However, challenges remain around resource limitations, regulatory guidance, technical capacity, and stigma.
Workshop 6 - Brainstorming & Policy Development session: Training, information and education of MDs
"Feedback from the 15 National Conferences"
Christel Nourissier, EURORDIS
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
EUnetHTA Planned and Ongoing Projects database (2014)EUnetHTA
The poster summarizes information about the EUnetHTA Planned and Ongoing Projects database. It notes that searches in the database are a standard procedure for 16-20% of partners on average, with similar topics found between partner projects 16-20% of the time. The database is used by over 50% of partners daily or weekly and provides email alerts of new projects. It is managed by various HTA organizations and agencies across Europe.
Dr Caroline Brown, Programme Manager, Influenza and Other Respiratory Pathogens, Thomas Hofmann, IHR Area Coordinator, Communicable Diseases and Health Security
Introduction to the breakout sessions & case studies presentationsEUPATI
This document discusses Romania's progress toward establishing a national EUPATI platform. It notes that patients are currently represented in law debates regarding the health system and hospital ethics committees, but not in committees for the Romanian Drug Agency or health technology assessment meetings. It then outlines the initial steps taken to form a national EUPATI liaison team, including identifying trainees, academic representatives, media partners, and representatives from healthcare professional bodies. The document concludes by describing how EUPATI can benefit patients and advocates in Romania by increasing health literacy and facilitating greater participation in clinical trials and health policy decisions.
This document summarizes a breakout group discussion from a EUPATI workshop on implementing the EUPATI project in countries where it is not already established. The group discussed how interested supporters in non-EUPATI countries could still work to establish EUPATI principles nationally by: looking for drivers and goals; requesting support materials from EUPATI; addressing potential hurdles; learning from other countries' experiences; and planning for sustainability without EUPATI funding. The breakout group represented 17 countries and identified steps individuals could take to advance patient involvement in medicines R&D where no formal EUPATI National Platform currently exists.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Presentation of the International Federation for Spina
Bifida and Hydrocephalus’ primary prevention study"
Pierre Mertens, International Federation for Spina Bifida and Hydrocephalus (IF)
A benefits case study describing how Diabetes UK has used HSCIC's data and statistical outputs to inform the Putting Feet First campaign. https://www.diabetes.org.uk/Get_involved/Campaigning/Our-campaigns/Putting-feet-first/
This document discusses post-Brexit implications for research and cooperation in Europe. It outlines how Brexit may impact the movement of staff in research and health industries, future data protection and clinical trial frameworks, and authorization of new medicines. It also summarizes several ongoing EU research initiatives on neurodegenerative diseases, including the Joint Programme for Neurodegenerative Disease Research (JPND) and Innovative Medicines Initiative (IMI), and EU Joint Actions on Dementia.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
The document summarizes a visit by a Flemish delegation to Edinburgh to learn about Scotland's health system, e-health initiatives, and digital health research. The delegation heard about Scotland's national health service, integrated care laws, e-health plan and research at Edinburgh University. They visited an NHS call center for telemonitoring patients. Key learnings included the central role of e-health in Scottish policy, pioneering work on integrated care, and using concrete goals and pilots to drive short and long-term innovations to ensure sustainability of the health system.
Global consultation on environmentally friendly procurement in the health sectorUNDP Eurasia
Dr. Christoph Hamelmann is the Regional Practice Leader for HIV at UNDP Europe and Central Asia. He presented at a global consultation on environmentally friendly procurement in the health sector. The presentation discussed establishing standards for "green" health sector procurement and capacity building for procurement officers and suppliers on sustainable practices. It also outlined a joint UN program to promote environmentally sound procurement policies across UN agencies for the health sector. The program aims to research best practices, train stakeholders, and increase awareness of sustainable procurement initiatives.
This document summarizes ECDC projects and collaborations on digital surveillance. It discusses two proof-of-concept studies: 1) Surveillance of pan-drug resistance which would use laboratory and electronic health record data through existing networks like WHONet. 2) Surveillance for priority diseases using electronic health records to describe cases with more complete risk factor data than currently available. The document outlines opportunities and challenges for these studies and proposes a multi-year implementation model to engage countries, address obstacles, and establish sustainable EU data flows and analyses.
Data protection ownership and portability a code of conduct for mHealth apps 3GDR
The document discusses data protection, ownership and portability in mHealth apps and whether current rules and regulations are fit for purpose. It provides an orientation on changing care models from hierarchical to integrated and from group-based to personalized. It reviews the history of mHealth and how technology is helping to achieve more affordable and personalized care. It then gives a status report on existing EU laws regarding medical devices, data protection and consumer rights as they apply to mHealth apps. It outlines member state actions and goals regarding mHealth as well as ongoing EU activities like a code of conduct and quality standards. Finally, it concludes that citizens must drive innovation, the digital divide must be avoided, and the legal framework works best with appropriate technology and governance.
The purpose of this case study summary is to briefly describe how stakeholders have used the prescriptions dispensed in the community publication to inform analytical, reporting and contract negotiation activities.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
This document provides guidance on using social media and communication tools effectively for patient organizations. It discusses how to create an online voice, examples from successful patient ambassadors, lessons from their experiences, and techniques for working smart with limited resources. Specific strategies and examples are provided for creating a meaningful brand difference, positioning an organization, running typical awareness and advocacy campaigns, and leveraging tools like social media, websites, videos, and crowdfunding campaigns.
COPD is a serious lung disease affecting 4-10% of European adults that is often preventable through reducing risk factors like smoking and air pollution. It places a high economic burden on healthcare systems and is expected to become the third leading cause of death worldwide by 2030. The document calls for 22 concrete actions the EU can take to improve COPD prevention, care, research, education and patient empowerment. These include increasing public awareness campaigns, strengthening tobacco control policies, improving screening and diagnosis, developing rehabilitation programs, increasing dedicated research funding, and supporting patient education initiatives.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
Mirjam Maeusezahl: Joint External Evaluations (JEE) – Country experiences: Sw...THL
The document discusses Switzerland's participation in the Joint External Evaluation (JEE) conducted by the World Health Organization. It provides details on Switzerland's implementation of the International Health Regulations, the timeline and milestones of the JEE process, and lessons learned. Key results showed room for improvement in antimicrobial resistance detection and response as well as strengthening surveillance systems for zoonotic diseases. Switzerland adapted the WHO National Action Plan template to monitor progress in addressing JEE recommendations internally.
Who workshop aids 2014 hivtb integrationZahed Islam
This document summarizes an AIDS 2014 workshop on increasing access to tuberculosis (TB) services for people who inject drugs in Ukraine through integrated care. It describes how non-governmental organizations (NGOs) in Ukraine provide TB screening, testing, and treatment to people who inject drugs through outreach programs and by establishing integrated care centers that provide medical and psychosocial support services for patients with drug abuse, HIV, and TB comorbidities in a single location. As of 2014, these efforts had established 88 opioid substitution therapy sites and detected 659 TB cases through screening over 10,000 people who inject drugs. However, challenges remain around resource limitations, regulatory guidance, technical capacity, and stigma.
Workshop 6 - Brainstorming & Policy Development session: Training, information and education of MDs
"Feedback from the 15 National Conferences"
Christel Nourissier, EURORDIS
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
EUnetHTA Planned and Ongoing Projects database (2014)EUnetHTA
The poster summarizes information about the EUnetHTA Planned and Ongoing Projects database. It notes that searches in the database are a standard procedure for 16-20% of partners on average, with similar topics found between partner projects 16-20% of the time. The database is used by over 50% of partners daily or weekly and provides email alerts of new projects. It is managed by various HTA organizations and agencies across Europe.
Dr Caroline Brown, Programme Manager, Influenza and Other Respiratory Pathogens, Thomas Hofmann, IHR Area Coordinator, Communicable Diseases and Health Security
Introduction to the breakout sessions & case studies presentationsEUPATI
This document discusses Romania's progress toward establishing a national EUPATI platform. It notes that patients are currently represented in law debates regarding the health system and hospital ethics committees, but not in committees for the Romanian Drug Agency or health technology assessment meetings. It then outlines the initial steps taken to form a national EUPATI liaison team, including identifying trainees, academic representatives, media partners, and representatives from healthcare professional bodies. The document concludes by describing how EUPATI can benefit patients and advocates in Romania by increasing health literacy and facilitating greater participation in clinical trials and health policy decisions.
This document summarizes a breakout group discussion from a EUPATI workshop on implementing the EUPATI project in countries where it is not already established. The group discussed how interested supporters in non-EUPATI countries could still work to establish EUPATI principles nationally by: looking for drivers and goals; requesting support materials from EUPATI; addressing potential hurdles; learning from other countries' experiences; and planning for sustainability without EUPATI funding. The breakout group represented 17 countries and identified steps individuals could take to advance patient involvement in medicines R&D where no formal EUPATI National Platform currently exists.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
Workshop 7 - Brainstorming & Policy Development session: Prevention
"Presentation of the International Federation for Spina
Bifida and Hydrocephalus’ primary prevention study"
Pierre Mertens, International Federation for Spina Bifida and Hydrocephalus (IF)
A benefits case study describing how Diabetes UK has used HSCIC's data and statistical outputs to inform the Putting Feet First campaign. https://www.diabetes.org.uk/Get_involved/Campaigning/Our-campaigns/Putting-feet-first/
This document discusses post-Brexit implications for research and cooperation in Europe. It outlines how Brexit may impact the movement of staff in research and health industries, future data protection and clinical trial frameworks, and authorization of new medicines. It also summarizes several ongoing EU research initiatives on neurodegenerative diseases, including the Joint Programme for Neurodegenerative Disease Research (JPND) and Innovative Medicines Initiative (IMI), and EU Joint Actions on Dementia.
The Innovative Medicines Initiative (IMI) is a public-private partnership between the European Union and the pharmaceutical industry that aims to boost pharmaceutical innovation in Europe. IMI supports pre-competitive research to accelerate the development of safer and more effective medicines through collaboration between stakeholders like industry, academia, patient organizations, and regulators. IMI is funded jointly by the EU and EFPIA members, with EU funds exclusively supporting public and nonprofit organizations and SMEs.
The document summarizes a visit by a Flemish delegation to Edinburgh to learn about Scotland's health system, e-health initiatives, and digital health research. The delegation heard about Scotland's national health service, integrated care laws, e-health plan and research at Edinburgh University. They visited an NHS call center for telemonitoring patients. Key learnings included the central role of e-health in Scottish policy, pioneering work on integrated care, and using concrete goals and pilots to drive short and long-term innovations to ensure sustainability of the health system.
Global consultation on environmentally friendly procurement in the health sectorUNDP Eurasia
Dr. Christoph Hamelmann is the Regional Practice Leader for HIV at UNDP Europe and Central Asia. He presented at a global consultation on environmentally friendly procurement in the health sector. The presentation discussed establishing standards for "green" health sector procurement and capacity building for procurement officers and suppliers on sustainable practices. It also outlined a joint UN program to promote environmentally sound procurement policies across UN agencies for the health sector. The program aims to research best practices, train stakeholders, and increase awareness of sustainable procurement initiatives.
This document summarizes ECDC projects and collaborations on digital surveillance. It discusses two proof-of-concept studies: 1) Surveillance of pan-drug resistance which would use laboratory and electronic health record data through existing networks like WHONet. 2) Surveillance for priority diseases using electronic health records to describe cases with more complete risk factor data than currently available. The document outlines opportunities and challenges for these studies and proposes a multi-year implementation model to engage countries, address obstacles, and establish sustainable EU data flows and analyses.
Data protection ownership and portability a code of conduct for mHealth apps 3GDR
The document discusses data protection, ownership and portability in mHealth apps and whether current rules and regulations are fit for purpose. It provides an orientation on changing care models from hierarchical to integrated and from group-based to personalized. It reviews the history of mHealth and how technology is helping to achieve more affordable and personalized care. It then gives a status report on existing EU laws regarding medical devices, data protection and consumer rights as they apply to mHealth apps. It outlines member state actions and goals regarding mHealth as well as ongoing EU activities like a code of conduct and quality standards. Finally, it concludes that citizens must drive innovation, the digital divide must be avoided, and the legal framework works best with appropriate technology and governance.
The purpose of this case study summary is to briefly describe how stakeholders have used the prescriptions dispensed in the community publication to inform analytical, reporting and contract negotiation activities.
A benefits case study describing how national stakeholders have used HSCIC's immunisation statistics to help drive improvements in immunisation services and inform decisions when managing disease outbreaks
This document provides guidance on using social media and communication tools effectively for patient organizations. It discusses how to create an online voice, examples from successful patient ambassadors, lessons from their experiences, and techniques for working smart with limited resources. Specific strategies and examples are provided for creating a meaningful brand difference, positioning an organization, running typical awareness and advocacy campaigns, and leveraging tools like social media, websites, videos, and crowdfunding campaigns.
COPD is a serious lung disease affecting 4-10% of European adults that is often preventable through reducing risk factors like smoking and air pollution. It places a high economic burden on healthcare systems and is expected to become the third leading cause of death worldwide by 2030. The document calls for 22 concrete actions the EU can take to improve COPD prevention, care, research, education and patient empowerment. These include increasing public awareness campaigns, strengthening tobacco control policies, improving screening and diagnosis, developing rehabilitation programs, increasing dedicated research funding, and supporting patient education initiatives.
1. The director of the EMCDDA discussed the evolution of HIV, drugs, and risk behavior in Europe based on lessons learned over decades. New HIV infections attributed to injecting drug use have declined significantly since the 1990s due to effective drug treatment and prevention programs.
2. However, regional disparities remain, and new outbreaks have been linked to stimulant use and new psychoactive substances. Maintaining prevention services and reaching vulnerable groups who are not in care will be important to address ongoing challenges.
3. Going forward, the EMCDDA aims to maintain understanding of drug use trends, identify new health threats to support rapid responses, promote effective interventions, and support policy development - all to contribute to
John F Ryan, Director, European Commission presenting at the EPA/HSE Environment & Health Conference, Dublin on the European Environment and Health Priorities
Fast-track the end of AIDS in the EU - practical evidence-based interventions.
Presentation by: John F. Ryan, Director, European Commission, DG SANTE
In a two-day meeting under the auspices of the Maltese Presidency of the Council of the European Union (30-31 January 2017), HIV experts from across the European Union discussed how to reverse this trend and how to prepare Europe to achieve the set target of ending AIDS by 2030.
Presentation made by Zsuzsanna Jakab, WHO Regional Director for Europe, at the meeting on Interdepartmental Plan for Public Health of Catalonia (PINSAP) Strategy and Programme, held in Barcelona, Spain on 14 February 2014.
Health 2020 is a new European policy framework for health and well-being adopted by the WHO Regional Committee for Europe in 2012. It aims to significantly improve population health and well-being, reduce health inequities, and ensure sustainable health systems. Health 2020 recognizes that health challenges require involvement across all levels of government and society. It provides an adaptable framework for integrated interventions to address major health issues like noncommunicable and communicable diseases.
Respiratory Diseases in European Health Priorities during the Polish Presiden...Global Risk Forum GRFDavos
GRF One Health Summit 2012, Davos: Presentation by Dr. Monika Przygucka-Gawlik - Councellor of the Minister - Department of Public Health - Ministry of Health - Poland
The document discusses WHO's new European policy for health called Health 2020. It aims to improve health and reduce health inequalities across Europe by tackling major health challenges like noncommunicable diseases, strengthening health systems, and creating supportive environments. The policy focuses on four priorities: improving leadership on health, investing in health across one's lifetime, addressing major diseases, and building resilient communities. It also discusses the impact of the economic crisis on health systems and policies to promote universal healthcare coverage and public health interventions.
This document summarizes the key points of the Commission Staff Working Document on prolonging the Action Plan on HIV/AIDS in the EU and neighbouring countries from 2014-2016. It discusses that while global HIV trends are declining, cases in Europe are rising. The original 2009-2013 plan achieved several goals but more work is needed on testing, treatment, harm reduction and addressing discrimination. This prolonged plan focuses on continued political leadership, treatment as prevention, and improving attention to co-infections like tuberculosis. An independent evaluation of the original plan will help inform future EU policy on HIV/AIDS.
The document discusses European Union action in the field of rare diseases, including establishing a legal basis, adopting programs and regulations, and outlining priorities and future actions. Key points include adopting an EU action program on rare diseases in 1999-2003, establishing an Orphan Medicinal Product Regulation in 2000, making rare diseases a priority in the Second EU Health Programme 2008-2013, and adopting a Commission Communication and Council Recommendation on rare diseases in 2008-2009 to guide member state plans and strategies.
The document discusses the targets and strategy of the Healthcare Innovation and Government Policy Department for 2016. The key priorities are to:
1) Identify priorities in the EU healthcare agenda and support awareness for ventricular assist devices and heart failure.
2) Identify lobbying mechanisms and key decision makers within the EU healthcare environment such as MEPs, medical associations, and committees.
3) Allocate funds to EU regions to develop advanced therapies for heart failure and conduct market and partnership analyses.
The document outlines the European Union's actions and priorities in the field of rare diseases. Key points include:
- Establishing a definition of rare diseases and improving disease classification.
- Supporting national plans and strategies for rare diseases in EU member states.
- Developing networks of centers of expertise and establishing European reference networks.
- Improving access to information, diagnosis, treatment and care for rare disease patients across Europe.
- Accelerating research and ensuring access to orphan drugs for rare diseases.
The document summarizes key points from a speech given by the WHO Regional Director for Europe on health challenges in the European region and strategies to address them. The main points are:
1) There are significant health inequities within and between countries in the European region in terms of life expectancy and healthy life expectancy. Nordic countries have some of the highest rates.
2) Investing in public health, disease prevention, and addressing social determinants of health through intersectoral policies can help reduce inequities and improve population health outcomes.
3) The Health 2020 policy framework and examples from countries like Norway that have strengthened public health infrastructure and implemented intersectoral governance approaches provide guidance for addressing challenges and closing
EN EN COMMISSION OF THE EUROPEAN COMMUNITIES Br.docxSALU18
EN EN
COMMISSION OF THE EUROPEAN COMMUNITIES
Brussels, 23.10.2007
COM(2007) 630 final
WHITE PAPER
Together for Health:
A Strategic Approach for the EU 2008-2013
(presented by the Commission)
{SEC(2007) 1374}
{SEC(2007) 1375}
{SEC(2007) 1376}
EN 2 EN
WHITE PAPER
Together for Health:
A Strategic Approach for the EU 2008-2013
1. WHY A NEW HEALTH STRATEGY?
Health is central in people's lives and needs to be supported by effective policies and actions
in Member States, at EC1 level and at global level.
Member States have the main responsibility for health policy and provision of healthcare to
European citizens. The EC's role is not to mirror or duplicate their work. However, there are
areas where Member States cannot act alone effectively and where cooperative action at
Community level is indispensable. These include major health threats and issues with a cross-
border or international impact, such as pandemics and bioterrorism, as well as those relating
to free movement of goods, services and people.
To carry out this role, cross-sectoral work is required. Article 152 of the EC Treaty says that a
"high level of human health protection shall be ensured in the definition and implementation
of all Community policies and activities". This Strategy reinforces the importance of health in
policies such as the Lisbon Strategy for Growth and Jobs, emphasising the links between
health and economic prosperity, and the Citizens' Agenda, recognising people's right to be
empowered in relation to their health and healthcare. Actions in the Strategy represent work
on health across all sectors. Health is found in Treaty articles on the Internal Market,
Environment, Consumer Protection, Social Affairs including the Safety and Health of
Workers, Development Policy, and Research, amongst many others2.
The EC's important role in health policy has been reaffirmed in the Reform Treaty which was
agreed by EU Heads of State and Government in Lisbon on 19 October 2007, and which
proposes to reinforce the political importance of health. A new overall aim on supporting
citizens' wellbeing is expected, as well as an encouragement of cooperation amongst Member
States on health and health services. Work on health at Community level adds value to
Member States' actions, particularly in the area of prevention of illness, including work on
food safety and nutrition, the safety of medical products, tackling smoking, legislation on
blood, tissues and cells, and organs, water and air quality, and the launch of a number of
health-related agencies. However, there are several growing challenges to the health of the
population which require a new strategic approach.
– Firstly, demographic changes including population ageing are changing disease patterns
and putting pressure on the sustainability of EU health systems. Supporting healthy ageing
means both promoting health throughout the lifespan, aiming to prevent h ...
1) Respiratory diseases such as COPD pose a major public health challenge globally and in Moldova.
2) A national strategy is needed to prevent onset and progression through education, limit risk factors like smoking and pollution, and screen at-risk populations.
3) The strategy should also accurately diagnose and treat COPD through quality testing, clinical assessments, and management of comorbidities, while educating patients to self-manage their condition.
This document discusses lifestyles and cancer prevention. It notes that unhealthy lifestyles like tobacco use, unhealthy diet, physical inactivity, and harmful alcohol use account for many cancers in Europe. International plans like the WHO Global Action Plan aim to reduce behavioral risk factors to prevent cancer and other diseases. The document then provides statistics on the most common cancers in Europe, noting variations in incidence rates across regions. It highlights monitoring of risk factors like those done by the Italian surveillance system PASSI as important for guiding prevention efforts. Finally, it introduces the next section which will discuss alcohol and its link to cancer.
The document summarizes the key outcomes of 15 national conferences on developing national plans for rare diseases held in European countries. The conferences discussed recommendations for defining strategic plans, indicators for monitoring plans, and delivering suggestions. Key messages focused on the need for socioeconomic research, empowering patient associations in research, developing quality registries, strengthening centers of expertise, training healthcare professionals, and empowering patients in decision-making.
The document provides recommendations for developing national plans to address rare diseases in European countries. It discusses key priorities that should be covered in national plans, including research, centers of expertise, information and patient services, gathering expert opinions, and empowering patient organizations. It also outlines elements of methodology for developing, managing, and evaluating national plans, such as governance structures, plan content, indicators, and funding. The overall goal is to build an integrated and comprehensive strategy across Europe to address the needs of rare disease patients.
This document summarizes a presentation about participating in the Active and Healthy Ageing European Innovation Partnership (EIP-AHA). It discusses what the EIP-AHA is, why participate, and the benefits and steps to get involved. Specifically, it provides an overview of the EIP-AHA's objectives to improve health, support sustainable healthcare systems, and enhance EU competitiveness. It outlines the EIP-AHA's working groups and examples of good practices being collected from various European regions to address challenges like chronic disease management and integrated care delivery. Finally, it describes the European Commission's role in supporting collaboration, evaluation, and enabling practice exchange to achieve the goals of increasing healthy life years.
Similar to Catherine Hartmann Secretary General of the European COPD Coalition (20)
Regione che vai, cura che trovi (forse). I principali risultati del XVII Rapporto sulle politiche della cronicità realizzato dal Coordinamento nazionale delle Associazioni dei Malati Cronici di Cittadinanzattiva
I principali dati del Rapporto annuale sulle politiche della cronicità realizzato da Coordinamento nazionale delle Associazioni dei Malati Cronici di Cittadinanzattiva. Presentazione dei principali dati a cura di Maria Teresa Bressi
La presentazione di Tonino Aceti, coordinatore nazionale del Tribunale per i diritti del malato di Cittadinanzattiva e direttore del Coordinamento nazionale delle Associazioni dei Malati Cronici delle principali proposte contenute nella Relazione 2018.
Arnaud Emerieu, President of the European Social Insurance Platform, BelgiumCittadinanzattiva onlus
The document outlines 5 priority areas for payers' perspectives on access to innovation: 1) Steering R&D to public health needs, 2) Ensuring evidence base for innovation through strengthened health technology assessment, 3) Strengthening national pricing and reimbursement mechanisms in interests of patients, payers and society, 4) Increasing transparency around innovative pharmaceuticals, and 5) Supporting innovation in context of sustainable healthcare systems. It advocates for transparent health technology assessment processes, voluntary collaboration between countries on pricing negotiations, ensuring access to medicines based on proven patient benefit, and promoting transparency around clinical trial data and pharmaceutical prices and expenditures to balance innovation and sustainability of health systems.
Sannié, member of the patients' consultative group of the French National Agency for Medicines and Health Product Safety, France, for European Patients' Rights Day 2017
The world's population is growing larger, older, and sicker, placing increasing challenges on healthcare systems to expand access to care with finite resources. Chronic diseases now account for 70% of illnesses, and the population over 50 will increase by over 500 million by 2025. Healthcare systems face constraints like aging populations, growing disease burdens, and limited budgets. However, new medical technologies in development and advances in data analytics provide optimism for healthier futures. Key questions remain around how to introduce high-value innovations and make systems more sustainable.
Alessia Squillace, Tribunal for Patients' Rights - A campaign on acces on inn...Cittadinanzattiva onlus
The Tribunale per i diritti del malato di Cittadinanzattiva promotes citizens' rights in health services in Italy with over 10,000 active citizens working out of 330 locations. New drugs for treating Hepatitis C offer a cure and simplify treatment but elevated prices and eligibility criteria limit access for many patients. The organization established a national tutelage program providing information, counseling, and monitoring access to the new drugs which has helped increase funding and prescription centers, expand eligibility criteria, and start over 53,000 patients on treatment, though access remains limited for some groups.
This document discusses ways to make access to innovative medicines more sustainable in the EU. It suggests the EU take a more comprehensive approach when negotiating medicine prices that considers public and private research contributions, product benefits, healthcare budget and organization impacts, and patent duration. It also recommends compulsory licensing be considered when prices are abnormally high. The role of regulators could be improved by expanding compassionate use programs, aligning regulatory and health technology assessment timelines, and increased post-approval monitoring. The EU should protect solidarity principles, encourage transparency, generalize orphan medicine access mechanisms, and encourage joint procurement to reduce prices.
Gottfried Endel, Main Association of Austrian Social Insurance Institutions, ...Cittadinanzattiva onlus
Gottfried Endel, Main Association of Austrian Social Insurance Institutions, Austria for 2017 European Patients' Rights Day in Brussels, "The payers' perspective on access to innovation"
Food safety, prepare for the unexpected - So what can be done in order to be ready to address food safety, food Consumers, food producers and manufacturers, food transporters, food businesses, food retailers can ...
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Bharat Mata - History of Indian culture.pdfBharat Mata
Bharat Mata Channel is an initiative towards keeping the culture of this country alive. Our effort is to spread the knowledge of Indian history, culture, religion and Vedas to the masses.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
The Antyodaya Saral Haryana Portal is a pioneering initiative by the Government of Haryana aimed at providing citizens with seamless access to a wide range of government services
AHMR is an interdisciplinary peer-reviewed online journal created to encourage and facilitate the study of all aspects (socio-economic, political, legislative and developmental) of Human Mobility in Africa. Through the publication of original research, policy discussions and evidence research papers AHMR provides a comprehensive forum devoted exclusively to the analysis of contemporaneous trends, migration patterns and some of the most important migration-related issues.
UN WOD 2024 will take us on a journey of discovery through the ocean's vastness, tapping into the wisdom and expertise of global policy-makers, scientists, managers, thought leaders, and artists to awaken new depths of understanding, compassion, collaboration and commitment for the ocean and all it sustains. The program will expand our perspectives and appreciation for our blue planet, build new foundations for our relationship to the ocean, and ignite a wave of action toward necessary change.
Jennifer Schaus and Associates hosts a complimentary webinar series on The FAR in 2024. Join the webinars on Wednesdays and Fridays at noon, eastern.
Recordings are on YouTube and the company website.
https://www.youtube.com/@jenniferschaus/videos
Catherine Hartmann Secretary General of the European COPD Coalition
1. Catherine Hartmann
Secretary General of the European COPD Coalition
Member of the European Chronic Disease Alliance
8th EU Patients Rights Day 12-13 May
Chronic diseases’ networks added value in policy making
Different successful models to networking
The European Chronic Disease Alliance (ECDA)
3. ECDA – a key stakeholder that brings value
Cancer
CVDs
Allergies
COPD &
asthma
Kidney
diseases
Diabetes
HCPS
Patients
Care takers
Liver
diseases
Researchers
4. ECDA’s structure
• Association de fait
• Full and Associate members
• Unanimously adopted decisions
• Professional secretariat
7. Benefits of Stakeholders involvement in
response to Chronic Diseases
• For the EU policymakers
• For the EU stakeholders
8. What ECDA does
Drafting white papers and statements, providing input to
consultations, sending letters, taking part in an EU Funded
project, press articles – advocacy tools are numerous
9. What ECDA does - 2
Meeting with key EU officials- and in particular, directors &
heads of unit at the DG SANCO:
DG SANCO representatives
EU Commissioner for health,
EU health award, Gastein 2010
10. ECDA Call for Action
Urgent political action is needed to reduce the human, social and
economic burden of chronic diseases.
We, as ECDA, representing millions of patients and over 100,000
health professionals call for:
11. EU framework on Chronic DiseasesEUadded-value
in collaboration
with relevant
stakeholders
by 2017
Intervene on
health
determinants
Incorporate
targets
Invest in
prevention
Strengthen
cooperation
Encourage
citizens to make
healthy choices
Ensure
availability of
comparable data
Enhance
cooperation on
research
Strengthen
monitoring and
evaluation
12. To recap – a Key Political Momentum for
CDs
ECDA five key Recommendations
1. The EU must adopt a comprehensive framework on chronic diseases that
leverages EU and MS regulatory competences and resources in all policies.
2. The EU must support MS in adapting health care systems to respond to the
growing burden of chronic diseases, ageing population and increasing
prevalence of co-morbidities.
3. The EU should introduce population-wide measures to reduce the key risk
factors.
4. Successful and proven harm reduction policies should also remain in place in
the MS and be properly resourced.
5. Monitoring and evaluating actions for chronic diseases should encompass
establishing EU-wide surveillance and screening programmes (EU registries).
13. Thank you
ECDA
Rue du Luxembourg 22-24 I 1000 Brussels | Belgium
Phone: +32 2 213 13 12
E-mail: info@alliancechronicdiseases.org
www.alliancechronicdiseases.org
Editor's Notes
Alliance of 11 European health organisations representing millions of chronic disease patients and over 100,000 health professionalsAllergic diseases, Cancers, Cardiovascular Diseases, COPD and all Respiratory Diseases, Diabetes, Hypertension, Kidney Diseases, Liver Diseases, Our missionTo reverse the alarming rise in chronic diseases by providing leadership and policy recommendations based on contemporary evidenceOur priorities - Primary and secondary prevention related to chronic diseases - Common risk factors: tobacco use, poor nutrition, physical inactivity, alcohol consumption, environmental factorsThe fact that ECDA is an alliance with a large coverage of diseases means that no emphasis is given on particular conditions – we look at and work on what we have in common, to influence EU decision makers, on subjects that will benefit all of the associations members of ECDA fight for
Unique health organization representing a wide range of CDs in EuropeWealth of expertise and resources to support the Commission in developing concrete actions on CDsGreat network across Europe, providing valuable access to data and information about CDsStrong commitment to actively contribute in shaping policies addressing health risk factors to secure the best outcome for the European citizensOpen to dialogue and keen to engage with all relevant stakeholders to protect and improve the health of European citizens
To achieve widespread, sustainable changeto create a bigger impact than is possible with grassroots programmes aloneto try to make programme impacts more sustainableto defend communities and programmes from adverse policy changesTo strengthen civil society and expand democratic space by:encouraging consultation and the participation of citizens in all levels of policy-making building and strengthening cooperation between NGOs and other civil groups,establishing through interactions with decision-makers the legitimacy and credibility of civil groups
Chronic Diseases areinterrelated, have common risk factors and are largely preventable.Yet, in Europe, 9 people out of 10 die of a Chronic Disease. Chronic diseases carry significant human costs (human suffering, reduced workforce, social exclusion, health inequalities etc.)70% to 80% of healthcare costs are spent on chronic diseases. This corresponds to €700 billion in the European Union and this number is expected to rise in the coming years.* 97% of health expenses are presently spent on treatment, only 3% is invested in prevention.**
For EU policy makersAllows for interactive decision-makingEnsures openness and inclusiveness through a consensus-oriented approachDemonstrates accountability towards final users and EU stakeholders community at largeIncreases legitimacy of policy measures takenFor the EU stakeholders: Increases likelihood that consensus positions are taken up by decision-makersAllows for health policies to better meet the needs of EU citizens
Drafting white papers and statements, providing input to consultations, sending letters, taking part in an EU Funded project, press articles – advocacy tools are numerousWhite Paper -‘Chronic Disease Alliance – A unified Prevention approach’ (October 2010) Input to Consultation on the Refection Process on Chronic Disease (February 2012)Open Letter to President Barroso (May 2013)EU funded Project addressing Economics of Chronic Diseases – EConDA (April 2013-April 2015)Joint Statement -Tackling alcohol related harm requires better actions (March 2014)Recently:Contribution to the conclusion of the EU Summit on Chronic DiseasesLetter to Commissioner for Health, Tonio Borg, April 2014
Meeting with DG Sanco, Heads of Unit: we have established an ongoing dialogue to allow ECDA to feed in the reflection on Chronic DiseasesMeeting EU Commissioner for health, Tonio Borg:to brief him about the scope, burden and impact of Chronic Diseases, from a stakeholders point of view.ECDA understands that the decision to hold an EU summit on CD was highly influenced by this meeting ECDA was granted the European Health Award 2010 at the 13th European Health Forum Gastein, 6-9 October 2010
ECDA call for action: An EU Framework on Chronic DiseasesWe believe that urgent political action is needed to reduce the human, social and economic burden of chronic diseases.We, as ECDA, representing millions of patients and over 100,000 health professionals call for:Recognise prevention and health promotion related to CDs as an investment with significant economic and welfare gainsEnsureHealthis well included in all EU policies Include clear targets such as: 25% reduction in mortality due to CDs by 2025 Propose a clear EU framework:Address the causal chain of health risks through preventative measures focused on key risk factors (tobacco, alcohol, physical inactivity, air quality) and early detection and screeningRecognise and facilitate EU harmonisation measures for the management of co-morbiditiesMeasure, monitor and report on actions taken by Member StatesFacilitate Streamlined EU research strategies for CDsFacilitate implementation of common health data standards and EU registries
To recap– a Key PoliticalMomentum for CDsECDA five key RecommendationsThe EU must adopt a comprehensive framework on chronic diseasesthat leverages EU and MS regulatory competences and resources in all policies.The EU must support MS in adapting health care systems to respond to the growing burden of chronic diseases, ageing population and increasing prevalence of co-morbidities.The EU should introduce population-wide measures to reduce the key risk factors.Successful and proven harm reduction policies should also remain in place in the MS and be properly resourced.Monitoring and evaluating actions for chronic diseases should encompass establishing EU-wide surveillance and screening programmes (EU registries).